GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » 5-Year RORE %

Immune Design (Immune Design) 5-Year RORE % : 0.00% (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Immune Design 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Immune Design's 5-Year RORE % for the quarter that ended in Dec. 2018 was 0.00%.

The industry rank for Immune Design's 5-Year RORE % or its related term are showing as below:

IMDZ's 5-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -7.41
* Ranked among companies with meaningful 5-Year RORE % only.

Immune Design 5-Year RORE % Historical Data

The historical data trend for Immune Design's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design 5-Year RORE % Chart

Immune Design Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
5-Year RORE %
Get a 7-Day Free Trial - - - - -

Immune Design Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immune Design's 5-Year RORE %

For the Biotechnology subindustry, Immune Design's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immune Design's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Immune Design's 5-Year RORE % falls into.



Immune Design 5-Year RORE % Calculation

Immune Design's 5-Year RORE % for the quarter that ended in Dec. 2018 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -1.43--1.33 )/( -9.45-0 )
=-0.1/-9.45
=1.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2018 and 5-year before.


Immune Design  (NAS:IMDZ) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Immune Design 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Immune Design's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immune Design (Immune Design) Business Description

Traded in Other Exchanges
N/A
Address
1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
Executives
William R Ringo director
David Baltimore director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya director, officer: President and CEO C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey 10 percent owner, other: Managing Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005

Immune Design (Immune Design) Headlines

From GuruFocus

RS Investment Exits LogMeIn, HMS Holdings in 3rd Quarter

By Tiziano Frateschi Tiziano Frateschi 10-04-2016

Immune Design Insider Buys Shares

By Kyle Ferguson Kyle Ferguson 10-03-2016